Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus

Pediatric Infectious Disease Journal

Volumn 18, Issue 5, 1999, Pages 432-439

  McIntosh, Kenneth ^a   Cooper, Ellen ^b   Xu, Jing ^c   Mirochnick, Mark ^b   Lindsey, Jane ^c   Jacobus, David ^d   Mofenson, Lynne ^e   Yogev, Ram ^f   Spector, Stephen A ^g   Sullivan, John L ^h   Sacks, Henry ⁱ   Kovacs, Andrea ^j   Nachman, Sharon ^k   Sleasman, John ^l   Bonagura, Vincent ^m   McNamara, James ⁿ  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Jacobus Pharmaceutical Co Inc   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j LAC USC MEDICAL CENTER   (United States)

^k STONY BROOK UNIVERSITY   (United States)

^l UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^m SCHNEIDER CHILDREN'S HOSPITAL   (United States)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

Dapsone; Pediatric human immunodeficiency virus infection; Pneumocystis carinii pneumonia

Indexed keywords

COTRIMOXAZOLE; DAPSONE;

ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; DAPSONE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; PNEUMONIA, PNEUMOCYSTIS; REGRESSION ANALYSIS;

EID: 0033036469     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199905000-00007     Document Type: Article

References (27)

1. Simonds RJ, Hughes WT, Feinberg J, Navin TR. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21(Suppl):S44-8.
2. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996;156:144-88.
3. Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and Toxoplasma encephalitis in HIV-infected patients. J Acq Immun Defic Syndr Hum Retrovirol 1997;15:104-14.
4. Mirochnick M, Michaels M, Clarke D, Brena A, Regan AM, Pelton S. Pharmacokinetics of dapsone in children. J Pediatr 1993;12:806-9.
5. Gatti G, Loy A, Casazza R, Miletich F, Cruciani M, Bassetti D. Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1995; 39:1101-6.
6. Cruciani M, Concia E, Gatti G, Fioredda F, Bassetti D. Dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994;13:80-1.
7. CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR 1991;40(RR-2):1-13.
8. CDC. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995;44(RR-4):1-11.
9. Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994.
10. Crowder MJ, Hand DJ. Analysis of repeated measures. London: Chapman and Hall, 1990.
11. Mirochnick M, Cooper E, McIntosh K, ACTG Protocol 179 Team. Pharmacokinetics of daily and weekly dapsone in HIV-infected children [Abstract 574]. In: Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28 to February 1, 1996. Alexandria, VA: Infectious Diseases Society of America, 1996.
12. Stavola JJ, Noel GJ. Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. Pedatr Infect Dis J 1993;12:644-7.
13. Nachman SA, Mueller BU, Mirochnick M, Pizzo P. High failure rate of dapsone and pentamidine as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994;13:1004-6.
14. Salmon-Ceron D, Fontbonne A, Saba J, et al. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995;172:656-64.
15. Jacobus DP. Randomization to iron supplementation of patients with advanced human immunodeficiency virus disease: an inadvertent but controlled study with results important for patient care. J Infect Dis 1996;173:1044-5.
16. Antinori A, Murri R, Ammassari A, et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995;9:1343-50.
17. Opravil M, Hirschel B, Luthy R. Does dapsone increase mortality when given for prophylaxis of Pneumocystis carinii pneumonia? AIDS 1996;10:1045-6.
18. Bozzette S, Finkelstein DM, Spector SA, et al. A randomized trial of three anti-Pneumocystis carinii agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
19. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of 3 regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1996;124:792-802.
20. El-Sadr W, Murphy R, Yurik T, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 1998;339:1339-95.
21. Viora M, De Luca A, D'Ambrosio A, Antinori A, Ortona E. In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother 1996;40:1294-7.
22. Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. J Clin Invest 1978;62:214-20.
23. Bozeman PM, Learn DB, Thomas EL. Inhibition of human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1882;44:553-63.
24. Beumont MG, Graziani A, Ubel PA, MacGregor RR. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med 1996;100: 611-6.
25. Blum RN, Miller LA, Gaggini LC, Conn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquired Immune Defic Syndr 1992;5:341-7.
26. Gatti G, Fioredda F, Lorusso C, Cruciani M, Bassetti D. Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia. Pediatr Infect Dis J 1996;15:183.
27. Gatti G, Merighi M, Hossein J, et al. Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1996;40:2743-8.